Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation.

Paver, Elizabeth C; Cooper, Wendy A; Colebatch, Andrew J; Ferguson, Peter M; Hill, Sean K; Lum, Trina; Shin, Joo-Shik; O'Toole, Sandra; Anderson, Lyndal; Scolyer, Richard A; Gupta, Ruta

Paver, Elizabeth C; Cooper, Wendy A; Colebatch, Andrew J; Ferguson, Peter M; Hill, Sean K; Lum, Trina; Shin, Joo-Shik; O'Toole, Sandra; Anderson, Lyndal; Scolyer, Richard A; Gupta, Ruta.

Afiliação

Paver EC; Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, NSW, Australia.
Cooper WA; Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, NSW, Australia; The University of Sydney, Sydney, NSW, Australia; Western Sydney University, Campbelltown, NSW, Australia.
Colebatch AJ; Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, NSW, Australia; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.
Ferguson PM; Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, NSW, Australia; The University of Sydney, Sydney, NSW, Australia; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.
Hill SK; Gold Coast University Hospital, Southport, Qld, Australia.
Lum T; Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, NSW, Australia.
Shin JS; Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, NSW, Australia; The University of Sydney, Sydney, NSW, Australia.
O'Toole S; Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, NSW, Australia; The University of Sydney, Sydney, NSW, Australia.
Anderson L; Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, NSW, Australia; The University of Sydney, Sydney, NSW, Australia; Western Sydney University, Campbelltown, NSW, Australia.
Scolyer RA; Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, NSW, Australia; The University of Sydney, Sydney, NSW, Australia; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.
Gupta R; Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, NSW, Australia; The University of Sydney, Sydney, NSW, Australia. Electronic address: ruta.gupta@health.nsw.gov.au.

Pathology ; 53(2): 141-156, 2021 Feb.

Article em En | MEDLINE | ID: mdl-33388161

Assuntos

Antígeno B7-H1/análise; Biomarcadores Tumorais/análise; Neoplasias; Carcinoma Hepatocelular/diagnóstico; Carcinoma Hepatocelular/patologia; Carcinoma Hepatocelular/terapia; Carcinoma Pulmonar de Células não Pequenas/diagnóstico; Carcinoma Pulmonar de Células não Pequenas/patologia; Carcinoma Pulmonar de Células não Pequenas/terapia; Carcinoma de Células Renais/diagnóstico; Carcinoma de Células Renais/patologia; Carcinoma de Células Renais/terapia; Carcinoma de Células de Transição/diagnóstico; Carcinoma de Células de Transição/patologia; Carcinoma de Células de Transição/terapia; Neoplasias Colorretais/diagnóstico; Neoplasias Colorretais/patologia; Neoplasias Colorretais/terapia; Testes Diagnósticos de Rotina; Neoplasias do Endométrio/diagnóstico; Neoplasias do Endométrio/patologia; Neoplasias do Endométrio/terapia; Feminino; Neoplasias de Cabeça e Pescoço/diagnóstico; Neoplasias de Cabeça e Pescoço/patologia; Neoplasias de Cabeça e Pescoço/terapia; Humanos; Inibidores de Checkpoint Imunológico/análise; Imuno-Histoquímica; Imunoterapia; Neoplasias Renais/diagnóstico; Neoplasias Renais/patologia; Neoplasias Renais/terapia; Neoplasias Hepáticas/diagnóstico; Neoplasias Hepáticas/patologia; Neoplasias Hepáticas/terapia; Masculino; Melanoma/diagnóstico; Melanoma/patologia; Melanoma/terapia; Gradação de Tumores; Neoplasias/diagnóstico; Neoplasias/patologia; Neoplasias/terapia; Prognóstico; Receptor de Morte Celular Programada 1/análise; Neoplasias de Mama Triplo Negativas/diagnóstico; Neoplasias de Mama Triplo Negativas/patologia; Neoplasias de Mama Triplo Negativas/terapia

Palavras-chave

Combined positive score; PD-L1; Programmed death ligand-1; immune cell score; immune checkpoint inhibitors; immunohistochemistry; immunotherapy; pathology; predictive biomarker; tumour and immune cell area score; tumour proportion score

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Biomarcadores Tumorais / Antígeno B7-H1 / Neoplasias Tipo de estudo: Diagnostic_studies / Prognostic_studies / Risk_factors_studies / Sysrev_observational_studies Aspecto: Implementation_research Idioma: En Revista: Pathology Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Austrália País de publicação: Reino Unido

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google